| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
GABAA receptor[1]
2'MeO6MF targets GABAA receptors, a class of ligand-gated ion channels that mediate inhibitory neurotransmission in the central nervous system. It is a positive allosteric modulator at α2β1γ2L and all α1-containing GABAA receptors. 2'MeO6MF also directly activates α2β2/3 and α2β2/3γ2L GABAA receptors. |
|---|---|
| ln Vitro |
2'MeO6MF (100-300 µM; 60 min) slightly shifts the binding of [3H]-flunitrazepam to the synaptic membranes in rat brain by 5–10%. In a concentration-dependent manner, 2'MeO6MF increases [3H]-muscimol binding to rat brain synaptic membranes, resulting in an apparent EC50=20.8 nM and a mean Emax of 219.8%[1]. At recombinant α1β2γ2L GABAA receptors produced in Xenopus M oocytes, 2'MeO6MF (1-300 µM) concentration-dependently improves the response evoked by a low dose of GABA. Without any direct activation, 2'MeO6MF amplifies the response that GABA elicits at recombinant α1β1,3η2L and α1β2 GABAA receptors[1]. Concentration-dependently, 2'MeO6MF (1-10 µM; 60 min) raises tonic inhibitory currents in granule cells[2]. In RAWblueTM macrophage cells, 2'MeO6MF (100-1000 µM; 6.5 h) suppresses the LPS-induced increase in NFkB activity[2].
2'MeO6MF enhances [3H]-muscimol binding to rat brain synaptic membranes in a concentration-dependent manner with an apparent EC50 of 20.8 nM. It enhances the response elicited by GABA at recombinant α1β2γ2L GABAA receptors. 2'MeO6MF increases tonic inhibitory currents in granule cells in a concentration-dependent manner. It inhibits LPS-induced increase of NFκB activity in RAWblue macrophage cells. |
| ln Vivo |
In the elevated plus maze and light/dark tests, 2'MeO6MF (1-100 mg/kg; ip) exhibits anxiolytic-like effects. Higher dosages of MeO6MF produce sedative effects in the holeboard, actimeter, and barbiturate-induced sleep time tests[1]. After a stroke, mice's layer 2/3 pyramidal neurons exhibit an increase in tonic currents when exposed to 30 mg/kg of MeO6MF IV[2]. 2'MeO6MF (0.1-30 mg/kg; ip) protects neurons and improves functional recovery in mice following localized cerebral ischemia[2].
2'MeO6MF displays anxiolytic-like effects in the elevated plus maze and light/dark tests in mice at 1-100 mg/kg i.p.. It induces sedative effects at higher doses. 2'MeO6MF (30 mg/kg i.p.) increases tonic currents in layer 2/3 pyramidal neurons of mice after stroke. It is neuroprotective and enhances functional recovery after focal cerebral ischemia in mice at 0.1-30 mg/kg i.p.. |
| Enzyme Assay |
The in vitro receptor binding assay for 2'MeO6MF involves measuring its modulation of GABAA receptor activity. The assay typically uses radioligand binding or electrophysiological techniques. 2'MeO6MF is incubated with GABAA receptors at various concentrations. The EC50 value is determined by fitting the modulation data to a dose-response curve.
|
| Cell Assay |
In vitro cellular assays for 2'MeO6MF typically use cell lines or Xenopus oocytes expressing GABAA receptors. Cells are treated with the compound at various concentrations. Receptor activity is measured using electrophysiological techniques or fluorescent-based assays. The compound's ability to modulate receptor function is quantified.
|
| Animal Protocol |
Animal/Disease Models: Male Balb-c mice (8-10 weeks, 25-35 g)[1]
Doses: 1, 10, 30, 100 mg/kg Route of Administration: Ip Experimental Results: No overt acute toxicity was observed. Exerted anxiolytic effects at low doses and sedative effects at high doses without myorelaxant effects. 2'MeO6MF has been evaluated in vivo in mouse models. It displays anxiolytic-like effects in the elevated plus maze and light/dark tests at 1-100 mg/kg i.p.. 2'MeO6MF (30 mg/kg i.p.) increases tonic currents in layer 2/3 pyramidal neurons of mice after stroke. It is neuroprotective and enhances functional recovery after focal cerebral ischemia in mice at 0.1-30 mg/kg i.p.. |
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 2'MeO6MF are not extensively documented. As a small molecule with a molecular weight of 266.29, the compound is expected to have reasonable bioavailability. It is brain-penetrant. Further pharmacokinetic studies, including assessments of absorption, distribution, metabolism, and excretion, are necessary to fully characterize its PK profile.
|
| Toxicity/Toxicokinetics |
Toxicological data for 2'MeO6MF are not extensively available in the public domain. As a research compound used for in vitro and in vivo studies, it has not undergone extensive toxicological evaluation. Standard cytotoxicity assays in cell lines may have been performed to assess safety margins. Further preclinical toxicology studies would be required before clinical development.
|
| References |
[1]. Karim N, et, al. 2'-Methoxy-6-methylflavone: a novel anxiolytic and sedative with subtype selective activating and modulating actions at GABA(A) receptors. Br J Pharmacol. 2012 Feb;165(4):880-96.
[2]. Clarkson AN, et, al. The flavonoid, 2'-methoxy-6-methylflavone, affords neuroprotection following focal cerebral ischaemia. J Cereb Blood Flow Metab. 2019 Jul;39(7):1266-1282. |
| Additional Infomation |
Sedatives and anxiolytics; structures are described in the first source.
2'MeO6MF (2'-Methoxy-6-methylflavone) is a synthetic flavonoid derivative that acts as a brain-penetrant positive allosteric modulator at α2β1γ2L and all α1-containing GABAA receptors. It has anxiolytic and sedative properties and offers neuroprotection. The compound has a molecular weight of 266.29. No clinical trials or regulatory approvals have been reported. |
| Molecular Formula |
C17H14O3
|
|---|---|
| Molecular Weight |
266.29
|
| Exact Mass |
266.094
|
| CAS # |
89112-85-6
|
| PubChem CID |
930492
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
3.777
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
20
|
| Complexity |
401
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=CC2=C(C=C1)OC(=CC2=O)C3=CC=CC=C3OC
|
| InChi Key |
QEIHFNZSIRWEBX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H14O3/c1-11-7-8-16-13(9-11)14(18)10-17(20-16)12-5-3-4-6-15(12)19-2/h3-10H,1-2H3
|
| Chemical Name |
2-(2-methoxyphenyl)-6-methylchromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7553 mL | 18.7765 mL | 37.5530 mL | |
| 5 mM | 0.7511 mL | 3.7553 mL | 7.5106 mL | |
| 10 mM | 0.3755 mL | 1.8777 mL | 3.7553 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
